JP2006506455A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2006506455A5 JP2006506455A5 JP2005501534A JP2005501534A JP2006506455A5 JP 2006506455 A5 JP2006506455 A5 JP 2006506455A5 JP 2005501534 A JP2005501534 A JP 2005501534A JP 2005501534 A JP2005501534 A JP 2005501534A JP 2006506455 A5 JP2006506455 A5 JP 2006506455A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- tert
- butylbenzoyl
- pyrrolidine
- carboxylic acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 125000000217 alkyl group Chemical group 0.000 claims 57
- 125000003118 aryl group Chemical group 0.000 claims 48
- 229910052739 hydrogen Inorganic materials 0.000 claims 42
- 125000001072 heteroaryl group Chemical group 0.000 claims 33
- -1 3-methoxy-4-tert-butylbenzoyl Chemical group 0.000 claims 28
- 125000000623 heterocyclic group Chemical group 0.000 claims 28
- 239000001257 hydrogen Substances 0.000 claims 26
- 150000002431 hydrogen Chemical class 0.000 claims 24
- 125000003710 aryl alkyl group Chemical group 0.000 claims 21
- 125000004122 cyclic group Chemical group 0.000 claims 20
- 150000001875 compounds Chemical class 0.000 claims 18
- 125000005843 halogen group Chemical group 0.000 claims 18
- 125000004093 cyano group Chemical group *C#N 0.000 claims 17
- 125000004446 heteroarylalkyl group Chemical group 0.000 claims 17
- 125000006367 bivalent amino carbonyl group Chemical group [H]N([*:1])C([*:2])=O 0.000 claims 16
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 16
- 125000004043 oxo group Chemical group O=* 0.000 claims 12
- 229920006395 saturated elastomer Polymers 0.000 claims 10
- 150000001732 carboxylic acid derivatives Chemical class 0.000 claims 9
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Chemical compound OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims 8
- 229910052799 carbon Inorganic materials 0.000 claims 8
- 125000005842 heteroatom Chemical group 0.000 claims 8
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 8
- 125000001424 substituent group Chemical group 0.000 claims 8
- 229910052757 nitrogen Inorganic materials 0.000 claims 7
- 150000003839 salts Chemical class 0.000 claims 6
- 239000012453 solvate Substances 0.000 claims 6
- 208000036142 Viral infection Diseases 0.000 claims 5
- 239000002253 acid Substances 0.000 claims 5
- 150000002148 esters Chemical class 0.000 claims 5
- 230000009385 viral infection Effects 0.000 claims 5
- 125000005160 aryl oxy alkyl group Chemical group 0.000 claims 4
- 125000005841 biaryl group Chemical group 0.000 claims 4
- 125000000753 cycloalkyl group Chemical group 0.000 claims 4
- 125000004415 heterocyclylalkyl group Chemical group 0.000 claims 4
- 125000001183 hydrocarbyl group Chemical group 0.000 claims 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 4
- 229910052760 oxygen Inorganic materials 0.000 claims 4
- 125000004430 oxygen atom Chemical group O* 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 229910052717 sulfur Inorganic materials 0.000 claims 4
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 238000013160 medical therapy Methods 0.000 claims 2
- CNJOQLFWCMXPPG-CDPAUJCKSA-N (2s,4r,5r)-1-(4-tert-butyl-3-methoxybenzoyl)-4-(1-hydroxyethyl)-2-(2-methylpropyl)-5-(1,3-thiazol-2-yl)pyrrolidine-2-carboxylic acid Chemical compound C1=C(C(C)(C)C)C(OC)=CC(C(=O)N2[C@](C[C@H]([C@@H]2C=2SC=CN=2)C(C)O)(CC(C)C)C(O)=O)=C1 CNJOQLFWCMXPPG-CDPAUJCKSA-N 0.000 claims 1
- GNSKKEXPOIMGRA-ZOIIRCJOSA-N (2s,4r,5r)-1-(4-tert-butyl-3-methoxybenzoyl)-4-(2-hydroxypropan-2-yl)-2-(2-methylpropyl)-5-(1,3-thiazol-2-yl)pyrrolidine-2-carboxylic acid Chemical compound C1=C(C(C)(C)C)C(OC)=CC(C(=O)N2[C@](C[C@H]([C@@H]2C=2SC=CN=2)C(C)(C)O)(CC(C)C)C(O)=O)=C1 GNSKKEXPOIMGRA-ZOIIRCJOSA-N 0.000 claims 1
- PFZUXBHTBAMAOS-OFUUFJSKSA-N (2s,4s,5r)-1-(3-bromo-4-tert-butylbenzoyl)-4-(ethoxymethyl)-2-(2-methylpropyl)-5-(1,3-thiazol-2-yl)pyrrolidine-2-carboxylic acid Chemical compound C1([C@@H]2N([C@@](CC(C)C)(C[C@@H]2COCC)C(O)=O)C(=O)C=2C=C(Br)C(=CC=2)C(C)(C)C)=NC=CS1 PFZUXBHTBAMAOS-OFUUFJSKSA-N 0.000 claims 1
- BBDXRCVFTQOLNZ-OFUUFJSKSA-N (2s,4s,5r)-1-(4-tert-butyl-3-chlorobenzoyl)-4-(ethoxymethyl)-2-(2-methylpropyl)-5-(1,3-thiazol-2-yl)pyrrolidine-2-carboxylic acid Chemical compound C1([C@@H]2N([C@@](CC(C)C)(C[C@@H]2COCC)C(O)=O)C(=O)C=2C=C(Cl)C(=CC=2)C(C)(C)C)=NC=CS1 BBDXRCVFTQOLNZ-OFUUFJSKSA-N 0.000 claims 1
- FECFCUYXLBBKBO-XCIGCYOISA-N (2s,4s,5r)-1-(4-tert-butyl-3-methoxybenzoyl)-2-(2-methylpropyl)-4-(prop-2-enoxymethyl)-5-(1,3-thiazol-2-yl)pyrrolidine-2-carboxylic acid Chemical compound C1=C(C(C)(C)C)C(OC)=CC(C(=O)N2[C@](C[C@H](COCC=C)[C@@H]2C=2SC=CN=2)(CC(C)C)C(O)=O)=C1 FECFCUYXLBBKBO-XCIGCYOISA-N 0.000 claims 1
- DHGFOQPHLMIWIF-XCIGCYOISA-N (2s,4s,5r)-1-(4-tert-butyl-3-methoxybenzoyl)-2-(2-methylpropyl)-4-(propoxymethyl)-5-(1,3-thiazol-2-yl)pyrrolidine-2-carboxylic acid Chemical compound C1([C@@H]2N([C@@](CC(C)C)(C[C@@H]2COCCC)C(O)=O)C(=O)C=2C=C(OC)C(=CC=2)C(C)(C)C)=NC=CS1 DHGFOQPHLMIWIF-XCIGCYOISA-N 0.000 claims 1
- GNSKKEXPOIMGRA-FCDUAZGNSA-N (2s,4s,5r)-1-(4-tert-butyl-3-methoxybenzoyl)-4-(2-hydroxypropan-2-yl)-2-(2-methylpropyl)-5-(1,3-thiazol-2-yl)pyrrolidine-2-carboxylic acid Chemical compound C1=C(C(C)(C)C)C(OC)=CC(C(=O)N2[C@](C[C@@H]([C@@H]2C=2SC=CN=2)C(C)(C)O)(CC(C)C)C(O)=O)=C1 GNSKKEXPOIMGRA-FCDUAZGNSA-N 0.000 claims 1
- BSBUQUPCVMXAIX-ZHCYEPILSA-N (2s,4s,5r)-1-(4-tert-butyl-3-methoxybenzoyl)-4-(ethoxymethyl)-2-(2-methylpropyl)-5-(1,3-thiazol-2-yl)pyrrolidine-2-carboxylic acid Chemical compound C1([C@@H]2N([C@@](CC(C)C)(C[C@@H]2COCC)C(O)=O)C(=O)C=2C=C(OC)C(=CC=2)C(C)(C)C)=NC=CS1 BSBUQUPCVMXAIX-ZHCYEPILSA-N 0.000 claims 1
- URHNVEKBTOYPNA-OFUUFJSKSA-N (2s,4s,5r)-1-(4-tert-butyl-3-methoxybenzoyl)-4-(methoxymethyl)-2-(2-methylpropyl)-5-(1,3-thiazol-2-yl)pyrrolidine-2-carboxylic acid Chemical compound C1([C@@H]2N([C@@](CC(C)C)(C[C@@H]2COC)C(O)=O)C(=O)C=2C=C(OC)C(=CC=2)C(C)(C)C)=NC=CS1 URHNVEKBTOYPNA-OFUUFJSKSA-N 0.000 claims 1
- MVXLYYMOZKDDSX-GDRRSRKRSA-N (2s,4s,5r)-1-(4-tert-butyl-3-methoxybenzoyl)-4-(methoxymethyl)-2-(2-methylpropyl)-5-pyridin-2-ylpyrrolidine-2-carboxylic acid Chemical compound C1([C@@H]2N([C@@](CC(C)C)(C[C@@H]2COC)C(O)=O)C(=O)C=2C=C(OC)C(=CC=2)C(C)(C)C)=CC=CC=N1 MVXLYYMOZKDDSX-GDRRSRKRSA-N 0.000 claims 1
- QUEDXIIQZYWKOH-NTOOTBGVSA-N (2s,4s,5r)-1-(4-tert-butyl-3-methylbenzoyl)-4-(ethoxymethyl)-2-(2-methylpropyl)-5-(1,3-thiazol-2-yl)pyrrolidine-2-carboxylic acid Chemical compound C1([C@@H]2N([C@@](CC(C)C)(C[C@@H]2COCC)C(O)=O)C(=O)C=2C=C(C)C(=CC=2)C(C)(C)C)=NC=CS1 QUEDXIIQZYWKOH-NTOOTBGVSA-N 0.000 claims 1
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims 1
- 125000006274 (C1-C3)alkoxy group Chemical group 0.000 claims 1
- XGQJFVPSDZWOII-UHFFFAOYSA-N 1-(1,3-thiazol-2-yl)pyrrolidine-2-carboxylic acid Chemical compound OC(=O)C1CCCN1C1=NC=CS1 XGQJFVPSDZWOII-UHFFFAOYSA-N 0.000 claims 1
- JQCSUVJDBHJKNG-UHFFFAOYSA-N 1-methoxy-ethyl Chemical group C[CH]OC JQCSUVJDBHJKNG-UHFFFAOYSA-N 0.000 claims 1
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 claims 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims 1
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical group CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims 1
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 claims 1
- 125000003545 alkoxy group Chemical group 0.000 claims 1
- VDNWMJNXQUIRGC-UHFFFAOYSA-N diethyl 1-(2-aminobenzoyl)-4-(1-hydroxyethyl)pyrrolidine-2,2-dicarboxylate Chemical compound CCOC(=O)C1(C(=O)OCC)CC(C(C)O)CN1C(=O)C1=CC=CC=C1N VDNWMJNXQUIRGC-UHFFFAOYSA-N 0.000 claims 1
- RXKSUQZUBGLJQC-UHFFFAOYSA-N diethyl 4-(1-hydroxyethyl)-1-(2-nitrobenzoyl)pyrrolidine-2,2-dicarboxylate Chemical compound CCOC(=O)C1(C(=O)OCC)CC(C(C)O)CN1C(=O)C1=CC=CC=C1[N+]([O-])=O RXKSUQZUBGLJQC-UHFFFAOYSA-N 0.000 claims 1
- LHTLMSMNROQTDU-UHFFFAOYSA-N diethyl 4-ethenyl-1-(2-nitrobenzoyl)pyrrolidine-2,2-dicarboxylate Chemical compound CCOC(=O)C1(C(=O)OCC)CC(C=C)CN1C(=O)C1=CC=CC=C1[N+]([O-])=O LHTLMSMNROQTDU-UHFFFAOYSA-N 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 125000000842 isoxazolyl group Chemical group 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 239000006186 oral dosage form Substances 0.000 claims 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
- 125000003373 pyrazinyl group Chemical group 0.000 claims 1
- 125000004076 pyridyl group Chemical group 0.000 claims 1
- 125000004213 tert-butoxy group Chemical group [H]C([H])([H])C(O*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 1
- 125000000335 thiazolyl group Chemical group 0.000 claims 1
- 125000001544 thienyl group Chemical group 0.000 claims 1
- 0 *C(C(CC(C1N)N)(*1C(O)=O)I)=O Chemical compound *C(C(CC(C1N)N)(*1C(O)=O)I)=O 0.000 description 5
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0224774A GB0224774D0 (en) | 2002-10-24 | 2002-10-24 | Compounds |
| GB0229470A GB0229470D0 (en) | 2002-12-18 | 2002-12-18 | Compounds |
| GB0317141A GB0317141D0 (en) | 2003-07-22 | 2003-07-22 | Compounds |
| PCT/EP2003/011813 WO2004037818A1 (en) | 2002-10-24 | 2003-10-22 | 1-acyl-pyrrolidine derivatives for the treatment of viral infections |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2006506455A JP2006506455A (ja) | 2006-02-23 |
| JP2006506455A5 true JP2006506455A5 (enExample) | 2006-12-07 |
Family
ID=32180212
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2005501534A Withdrawn JP2006506455A (ja) | 2002-10-24 | 2003-10-22 | ウイルス感染症の治療のための１−アシル−ピロリジン誘導体 |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US7304087B2 (enExample) |
| EP (1) | EP1554274B1 (enExample) |
| JP (1) | JP2006506455A (enExample) |
| KR (1) | KR20050057670A (enExample) |
| AR (1) | AR041816A1 (enExample) |
| AT (1) | ATE418554T1 (enExample) |
| AU (1) | AU2003276172A1 (enExample) |
| BR (1) | BR0315417A (enExample) |
| CA (1) | CA2503471A1 (enExample) |
| CO (1) | CO5550450A2 (enExample) |
| DE (1) | DE60325498D1 (enExample) |
| IS (1) | IS7851A (enExample) |
| MA (1) | MA27524A1 (enExample) |
| MX (1) | MXPA05004435A (enExample) |
| NO (1) | NO20052472L (enExample) |
| PL (1) | PL376454A1 (enExample) |
| TW (1) | TW200418848A (enExample) |
| WO (1) | WO2004037818A1 (enExample) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0304494D0 (en) * | 2003-02-27 | 2003-04-02 | Glaxo Group Ltd | Compounds |
| GB0408995D0 (en) * | 2004-04-22 | 2004-05-26 | Glaxo Group Ltd | Compounds |
| GB0423673D0 (en) * | 2004-10-25 | 2004-11-24 | Glaxo Group Ltd | Compounds |
| GB0423672D0 (en) * | 2004-10-25 | 2004-11-24 | Glaxo Group Ltd | Compounds |
| WO2006050035A1 (en) | 2004-10-29 | 2006-05-11 | Schering Corporation | Substituted 5-oxo pyrazoles and [1,2,4]triazoles as antiviral agents |
| GB0519486D0 (en) * | 2005-09-23 | 2005-11-02 | Glaxo Group Ltd | Compounds |
| GB0519478D0 (en) * | 2005-09-23 | 2005-11-02 | Glaxo Group Ltd | Compounds |
| GB0519485D0 (en) * | 2005-09-23 | 2005-11-02 | Glaxo Group Ltd | Compounds |
| GB0519488D0 (en) * | 2005-09-23 | 2005-11-02 | Glaxo Group Ltd | Compounds |
| WO2008106166A2 (en) | 2007-02-28 | 2008-09-04 | Conatus Pharmaceuticals, Inc. | Methods for the treatment of liver diseases using specified matrix metalloproteinase (mmp) inhibitors |
| MX2009011930A (es) | 2007-05-04 | 2009-11-18 | Vertex Pharma | Terapia de combinacion para el tratamiento de infeccion de virus de hepatitis c. |
| US20090053175A1 (en) * | 2007-08-24 | 2009-02-26 | Yat Sun Or | Substitute pyrrolidine derivatives |
| EP2272832A4 (en) | 2008-04-28 | 2011-09-07 | Asahi Kasei Pharma Corp | PHENYLPROPIONIC ACID DERIVATIVE AND USE THEREOF |
| UA103195C2 (uk) | 2008-08-11 | 2013-09-25 | Глаксосмитклайн Ллк | Похідні пурину для застосування у лікуванні алергій, запальних та інфекційних захворювань |
| BRPI0917458A2 (pt) | 2008-08-11 | 2015-12-01 | Glaxosmithkline Llc | composto, método de tratamento de doenças e condições, composição farmacêutica, método para tratar ou prevenir doença, e, uso de um composto |
| CN102176911B (zh) | 2008-08-11 | 2014-12-10 | 葛兰素史密丝克莱恩有限责任公司 | 新的腺嘌呤衍生物 |
| US8575340B2 (en) | 2010-02-10 | 2013-11-05 | Glaxosmithkline Llc | Purine derivatives and their pharmaceutical uses |
| RS53745B1 (sr) | 2010-02-10 | 2015-06-30 | Glaxosmithkline Llc | 6-amino-2-{[(1s)-1-metilbutil]oksi}-9-[5-(1-piperidinil)pentil]-7,9-dihidro-8h-purin-8-on-maleat |
| WO2013134012A1 (en) | 2012-03-06 | 2013-09-12 | Merck Sharp & Dohme Corp. | Preparation and use of bicyclic himbacine derivatives as par-receptor antagonists |
| KR20160124157A (ko) | 2014-02-20 | 2016-10-26 | 글락소스미스클라인 인털렉츄얼 프로퍼티 (넘버 2) 리미티드 | 인간 인터페론의 유도인자로서의 피롤로[3,2]피리미딘 유도체 |
| ES2917887T3 (es) | 2014-11-13 | 2022-07-12 | Glaxosmithkline Biologicals Sa | Derivados de adenina que son útiles en el tratamiento de enfermedades alérgicas u otras afecciones inflamatorias |
| JP6411676B2 (ja) | 2015-12-03 | 2018-10-24 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ | Ｓｔｉｎｇの調節因子としての環状プリンジヌクレオチド |
| WO2017175156A1 (en) | 2016-04-07 | 2017-10-12 | Glaxosmithkline Intellectual Property Development Limited | Heterocyclic amides useful as protein modulators |
| SG10201900628RA (en) | 2016-04-07 | 2019-02-27 | Glaxosmithkline Ip Dev Ltd | Heterocyclic amides useful as protein modulators |
| US11377440B2 (en) | 2017-10-05 | 2022-07-05 | Glaxosmithkline Intellectual Property Development Limited | Modulators of stimulator of interferon genes (STING) |
| AU2018344902B2 (en) | 2017-10-05 | 2021-06-03 | Glaxosmithkline Intellectual Property Development Limited | Modulators of stimulator of interferon genes (STING) useful in treating HIV |
| GB201807924D0 (en) | 2018-05-16 | 2018-06-27 | Ctxt Pty Ltd | Compounds |
| US20220251079A1 (en) | 2019-05-16 | 2022-08-11 | Stingthera, Inc. | Benzo[b][1,8]naphthyridine acetic acid derivatives and methods of use |
| JP2022533390A (ja) | 2019-05-16 | 2022-07-22 | スティングセラ インコーポレイテッド | オキソアクリジニル酢酸誘導体および使用方法 |
| GB201910305D0 (en) | 2019-07-18 | 2019-09-04 | Ctxt Pty Ltd | Compounds |
| GB201910304D0 (en) | 2019-07-18 | 2019-09-04 | Ctxt Pty Ltd | Compounds |
| WO2021119753A1 (en) | 2019-12-18 | 2021-06-24 | Ctxt Pty Limited | Compounds |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU5687396A (en) | 1995-04-21 | 1996-11-07 | Novarits Ag | N-aroylamino acid amides as endothelin inhibitors |
| AU1804299A (en) | 1997-12-08 | 1999-06-28 | Glycomed Incorporated | Sialyl lewis x and sialyl lewis a glycomimetics |
| EP1051104B1 (en) | 1998-01-26 | 2008-04-09 | Massachusetts Institute Of Technology | Fluorescence imaging endoscope |
| WO1999054299A1 (en) | 1998-04-23 | 1999-10-28 | Abbott Laboratories | Pyrrolidines as inhibitors of neuraminidases |
| US6323180B1 (en) | 1998-08-10 | 2001-11-27 | Boehringer Ingelheim (Canada) Ltd | Hepatitis C inhibitor tri-peptides |
| EP1118287B1 (de) * | 2000-01-21 | 2004-11-24 | Alois Ing. Sampl | Steckbares Regalsystem |
| EP1278743A4 (en) | 2000-05-05 | 2003-05-14 | Smithkline Beecham Corp | NEW ANTI-INFECTIOUS ACTIVE SUBSTANCES |
| JP2004536779A (ja) | 2000-11-20 | 2004-12-09 | サイオス インコーポレイテッド | ｐ３８キナーゼのインドール型阻害剤 |
| JP2005511574A (ja) | 2001-10-26 | 2005-04-28 | ファルマシア アンド アップジョン カンパニー リミティド ライアビリティー カンパニー | Ｎａｃｈｒアゴニストとしてのｎ−アザビシクロ−置換ヘテロ二環式カルボキサミド |
| WO2003037893A1 (en) | 2001-11-02 | 2003-05-08 | Glaxo Group Limited | Acyl dihydro pyrrole derivatives as hcv inhibitors |
| US20060167702A1 (en) | 2002-10-28 | 2006-07-27 | Pierre-Paul Jodoin | Method of preventing theft to vehicles using intensive marking |
-
2003
- 2003-10-22 TW TW092129213A patent/TW200418848A/zh unknown
- 2003-10-22 DE DE60325498T patent/DE60325498D1/de not_active Expired - Fee Related
- 2003-10-22 CA CA002503471A patent/CA2503471A1/en not_active Abandoned
- 2003-10-22 PL PL03376454A patent/PL376454A1/xx not_active Application Discontinuation
- 2003-10-22 EP EP03809322A patent/EP1554274B1/en not_active Expired - Lifetime
- 2003-10-22 AU AU2003276172A patent/AU2003276172A1/en not_active Abandoned
- 2003-10-22 WO PCT/EP2003/011813 patent/WO2004037818A1/en not_active Ceased
- 2003-10-22 AT AT03809322T patent/ATE418554T1/de not_active IP Right Cessation
- 2003-10-22 MX MXPA05004435A patent/MXPA05004435A/es unknown
- 2003-10-22 KR KR1020057006957A patent/KR20050057670A/ko not_active Withdrawn
- 2003-10-22 BR BR0315417-3A patent/BR0315417A/pt not_active IP Right Cessation
- 2003-10-22 US US10/531,884 patent/US7304087B2/en not_active Expired - Fee Related
- 2003-10-22 AR ARP030103852A patent/AR041816A1/es not_active Application Discontinuation
- 2003-10-22 JP JP2005501534A patent/JP2006506455A/ja not_active Withdrawn
-
2005
- 2005-04-25 CO CO05038997A patent/CO5550450A2/es not_active Application Discontinuation
- 2005-05-06 MA MA28263A patent/MA27524A1/fr unknown
- 2005-05-19 IS IS7851A patent/IS7851A/is unknown
- 2005-05-23 NO NO20052472A patent/NO20052472L/no not_active Application Discontinuation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2017276170B2 (en) | Sulphamoylpyrrolamide derivatives and the use thereof as medicaments for the treatment of Hepatitis B | |
| CA2774647C (en) | Substituted amide compound | |
| JP2019077725A5 (enExample) | ||
| JP2021534124A5 (enExample) | ||
| JP2004502670A5 (enExample) | ||
| JP2006524222A5 (enExample) | ||
| JP2007523905A5 (enExample) | ||
| FI3625233T3 (fi) | 3-(((((2s,5r)-2-karbamoyyli-7-okso-1,6-diatsabisyklo[3.2.1]oktan-6-yyli)oksi)sulfonyyli)oksi)-2,2-dimetyylipropanoaattijohdannaisia ja niihin liittyviä yhdisteitä beetalaktamaasiestäjien suun kautta otettavina aihiolääkkeinä bakteeri-infektioiden hoitamiseksi | |
| RU2010146384A (ru) | Пирролидиноновые активаторы глюкокиназы | |
| EP1440070A1 (en) | 4-(5-membered)-heteroaryl acyl pyrrolidine derivatives as hcv inhibitors | |
| CA2529686C (en) | 2-acylaminothiazole derivative or salt thereof | |
| JP2005515172A5 (enExample) | ||
| JP2010526129A5 (enExample) | ||
| JP2007523142A5 (enExample) | ||
| JP4607107B2 (ja) | シクロプロピル基置換されたオキサゾリジノン抗生物質およびこれらの誘導体 | |
| RU2013112744A (ru) | Алкил 2-{[(2r,3s,5r)-5-(4-амино-2-оксо-2н-пиримидин-1-ил)-гидрокси-тетрагидро-фуран-2-илметокси]-фенокси-фосфориламино}-пропионаты, нуклеозидные ингибиторы рнк-полимеразы hcv ns5b, способы их получения и применения | |
| RU2010134411A (ru) | Фенилацетамидное производное | |
| RU2010134361A (ru) | Производные изоксазола в качестве модуляторов 11-бета-гидроксистероиддегидрогеназы 1 типа | |
| JP2018505145A5 (enExample) | ||
| JP2008516922A5 (enExample) | ||
| JP2016540811A5 (enExample) | ||
| RU2007119390A (ru) | Соединения 4-метоксиметил-пирролидин-2-карбоновой кислоты и их производные - ингибиторы вируса гепатита с | |
| JP2018515489A5 (enExample) | ||
| JP2014513122A5 (enExample) | ||
| JP2009514801A5 (enExample) |